Evicenter
P&T meetings

Saroglitazar

Primary biliary cholangitis

Manufacturer
Zydus Therapeutics
Regulatory submission
NDA submitted by May 2026
Last updated
81 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Primary biliary cholangitis

Economic burden and healthcare resource utilization

4 evidence topics · 4 sources

U.S. inpatient costs by treatment line

“Patients in the untreated cohort had the highest mean IP costs during the follow-up period (untreated: $37,974; 1L: $5854; 2L+: $6898).” (opens the source at this quote in a new tab)

Pruritus-associated healthcare utilization and costs

“one-year adjusted healthcare costs averaged $39 949 for pruritus and $25 695 for controls” (opens the source at this quote in a new tab)

Fatigue or pruritus: matched case-control study

“total healthcare costs (mean cost difference: fatigue, $42,515; pruritus $40,536).” (opens the source at this quote in a new tab)

Population-based cost-of-illness study

“The economic burden of Primary Biliary Cholangitis (PBC) has not been investigated at population-level.” (opens the source at this quote in a new tab)